AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KSEP 151 min read$PLSE

PULSE BIOSCIENCES, INC. (PLSE): Entry into a Material Definitive Agreement

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 15, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with Mizuho Securities USA LLC (“Mizuho”) as sales agent, pursuant to which the Company may o

Original reporting
SEC EDGAR 8-K
Published Sep 15, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$PLSE
Neutral
high confidence
Mentioned
$PLSE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PLSENeutralMed
01

Why it matters

The new $85M agreement expands fundraising capacity, indicating confidence in pipeline but introduces dilution risk.

02

Market read

Primary disclosure of a material capital‑raising agreement; relevant for investors monitoring dilution and cash‑flow prospects.

03

What to watch

Potential strategic partnership with Mizuho could improve distribution efficiency and market visibility.

Relevance 6/10Novelty 8/10Timing: same‑day filing September 15 2026

Background

Pulse Biosciences is a clinical‑stage medical‑device company that previously raised $68.8M under a similar agreement.

Company-level read

Ticker impact

$PLSENeutralHigh confidence
Context

Pulse Biosciences filed an 8‑K reporting a new equity distribution agreement to sell up to $85 million of common stock.

Expected impact

Modest upside if capital is deployed efficiently, but possible short‑term pressure from dilution concerns.

Evidence & confidence

First disclosure of a sizable at‑the‑market offering; market will price in financing terms and dilution.

Market effects

Sector

May signal increased financing activity in the biotech/medical‑device sector.

Regional

Limited to U.S. markets where PLSE trades.

Global

Low global impact beyond niche investors.

Counterpoint

What could challenge this read

If the capital raise is not needed, the dilution could outweigh benefits, pressuring the stock.

Key entities

  • Agent
    Mizuho Securities USA LLC

    Designated sales agent for the equity distribution.

  • Legal Counsel
    Baker & Hostetler LLP

    Provided legal opinion on the share issuance.

Read at source← All news

Related articles

OCT 8
$PLSEMedAI 8/10

How Trial Enrollment Completion At Pulse Biosciences (PLSE) Has Changed Its Investment Story

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

simplywall.st3 min
OCT 7
$PLSEMedAI 8/10

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls

SEC EDGAR 8-K2 min
OCT 7
$PLSELowAI 8/10

Pulse Biosciences completes enrollment in cardiac ablation study

Pulse Biosciences (PLSE) completed enrollment in its NANOPULSE-AF Study for treating atrial fibrillation, hitting its 164-patient target three months early. The study evaluates the safety and effectiveness of its nPulse Cardiac Catheter System. Primary endpoints will be assessed at six and 12 months post-ablation. The company plans to share updates and present data at future conferences.

investing.com1 min
OCT 6
$PLSEMed

Canaccord raises Pulse Biosciences stock price target on tech potential

Canaccord raised its price target on Pulse Biosciences (PLSE) to $58 from $43, maintaining a Buy rating. The stock has surged 87.5% since Canaccord initiated coverage and 268% year-to-date, with a $3.6B market cap. The firm cited the company's nanosecond pulse field ablation platform and clinical progress. Pulse also announced an equity distribution agreement with Mizuho Securities for up to $85M in common stock sales.

investing.com2 min
SEP 15
$PLSEMedAI 8/10

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic…

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed

SEC EDGAR 8-K1 min